Perspective Therapeutics

Booth: (no booth)

Bronze Sponsor

United States

Perspective Therapeutics is a clinical-stage radiopharmaceutical company developing targeted alpha therapies using the isotope Pb-212. Formed in 2023 through the merger of Viewpoint Molecular Targeting and Isoray, the company focuses on delivering highly selective radiation directly to cancer cells via high-affinity targeting peptides.

Their theranostic platforms pair Pb-212 for treatment with Pb-203 for imaging, enabling physicians to verify target expression and biodistribution before therapy. This approach supports personalized patient selection while minimizing toxicity. With proprietary peptide technologies, optimized chelators, and expanding Pb-212 manufacturing capabilities, Perspective Therapeutics is advancing a strong clinical pipeline supported by international research partnerships.